Literature DB >> 12841190

Gefitinib.

Mohamed Muhsin1, Joanne Graham, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12841190     DOI： 10.1038/nrd1136

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  29 in total

1.  Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors.

Authors:  Zachary B Hill; B Gayani K Perera; Simeon S Andrews; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2011-12-22       Impact factor: 5.100

2.  An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

Authors:  Klaus Godl; Josef Wissing; Alexander Kurtenbach; Peter Habenberger; Stephanie Blencke; Heidrun Gutbrod; Kostadinos Salassidis; Matthias Stein-Gerlach; Andrea Missio; Matt Cotten; Henrik Daub
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

3.  Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.

Authors:  Brian Madajewski; Feng Chen; Barney Yoo; Melik Z Turker; Ulrich Wiesner; Michelle S Bradbury; Cameron Brennan; Kai Ma; Li Zhang; Pei-Ming Chen; Rupa Juthani; Virginia Aragon-Sanabria; Mithat Gonen; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2020-07-28       Impact factor: 12.531

4.  Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks.

Authors:  Kalpana K Bhanumathy; Omar Abuhussein; Frederick S Vizeacoumar; Andrew Freywald; Franco J Vizeacoumar; Christopher P Phenix; Eric W Price; Ran Cao
Journal:  Methods Mol Biol       Date:  2021

5.  FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.

Authors:  Sun-Young Lee; Roland Meier; Saori Furuta; Marc E Lenburg; Paraic A Kenny; Ren Xu; Mina J Bissell
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

6.  In Ovo and In Silico Evaluation of the Anti-Angiogenic Potential of Syringin.

Authors:  Charlaine A Aventurado; Junie B Billones; Ross D Vasquez; Agnes L Castillo
Journal:  Drug Des Devel Ther       Date:  2020-11-25       Impact factor: 4.162

7.  Antimicrobial Study of Newly Synthesized Lanthanide(III) Complexes of 2-[2-hydroxy-3-methoxyphenyl]-3-[2-hydroxy-3-methoxybenzylamino]-1,2-dihydroquinazolin-4(3H)-one.

Authors:  Kalagouda B Gudasi; Vidyadhar C Havanur; Siddappa A Patil; Basavaraj R Patil
Journal:  Met Based Drugs       Date:  2007

8.  Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.

Authors:  Zeenat Mirza; Hans-Juergen Schulten; Hasan Ma Farsi; Jaudah A Al-Maghrabi; Mamdooh A Gari; Adeel Ga Chaudhary; Adel M Abuzenadah; Mohammed H Al-Qahtani; Sajjad Karim
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

9.  An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.

Authors:  Young-Ki Bae; Jee Young Sung; Yong-Nyun Kim; Sunshin Kim; Kyeong Man Hong; Heung Tae Kim; Min Sung Choi; Jae Young Kwon; Jaegal Shim
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

10.  MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer.

Authors:  Xiaoping Wu; Tianchi Liu; Ou Fang; Wenhua Dong; Fengjun Zhang; Lindsey Leach; Xiaohua Hu; Zewei Luo
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.